Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Hypodermic Syringes and Needles Market Size & Share 2026-2035
Report ID: GMI5556
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Hypodermic Syringes and Needles Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Hypodermic Syringes & Needles Market Size
The hypodermic syringes & needles market was valued at USD 7.58 billion in 2025, is projected to reach USD 7.85 billion in 2026, is expected to expand at a 3.55% CAGR (2026–2035), and is forecast to reach USD 10.75 billion by 2035.
Hypodermic Syringes and Needles Market Key Takeaways
Market Leader: B. Braun Melsungen led with over 7.4% market share in 2025.
Leading Players: Top 5 players in this market include B. Braun Melsungen, BD Becton Dickinson and Company), Cardinal Health, HMD Healthcare, Nipro, which collectively held a market share of 23.5% in 2025.
The hypodermic syringes & needles market is moving from a predominantly high-volume consumables model toward a more differentiated mix led by safety-engineered and specialty injection formats. Chronic injectable therapies, routine immunization programs, and the migration of care into ambulatory and home settings are reshaping purchasing channels while supporting recurring demand for compliant, single-use devices.
GMI Analyst View
Based on our discussions with industry experts and our proprietary review of company revenue disclosures and procurement trade data, the global hypodermic syringes and needles market generated USD 7.25 billion in 2024, confirming that growth momentum into the 2025 base year was sustained by accelerating safety-device adoption and robust vaccine-procurement demand even as pandemic-elevated syringe consumption in high-income markets fully normalized.
Hypodermic Syringes & Needles Market Trends, Growth Drivers & GMI Forecast Outlook
Demand is increasingly shaped by the interaction of chronic-care delivery, public-health procurement, and safety regulation. Growth opportunities are strongest where recurring injection needs coincide with conversion to higher-specification devices, although weak waste-management capacity and rational prescribing policies limit how fully latent demand is translated into device revenue.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Chronic injectable therapy is altering both the scale and route to market for needles and syringes. Diabetes care increasingly depends on self-administration, which shifts a portion of purchasing from centralized hospital tenders toward pharmacies, distributors, and direct-to-patient channels. That transition rewards suppliers that can pair reliable availability with formats suited to frequent use, including pen needles and safety-focused products.
Vaccination procurement creates an unusually stable demand layer because its purchase cycles are organized around population coverage rather than discretionary clinical spending. UNICEF supplies an average of 800 million auto-disable syringes annually for childhood vaccination programs across more than 90 countries [5]UNICEF Supply Division. “Safe injection equipment.” unicef.org. The resulting tender base supports producers with quality credentials, scale, and the capacity to meet evolving product specifications without disrupting supply continuity.
Safety regulation is also changing the market's revenue mix. As ministries, hospitals, and accreditation bodies move from conventional devices toward reuse-prevention and sharps-protection formats, device suppliers can capture a greater share of value through validated designs rather than relying solely on unit-volume expansion. The conversion process is gradual, particularly in cost-sensitive public systems, but it creates a durable upgrade cycle for compliant portfolios.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Waste management is a commercial as well as a public-health constraint. Facilities that lack reliable sharps collection, treatment, or disposal systems face a higher operational burden when expanding single-use injection-device procurement. This is especially consequential in rural and peripheral care settings, where clinical need may rise faster than the infrastructure needed to manage used devices safely.
The effect is amplified in fragile settings, where procurement cycles, distribution networks, and disposal capacity can all be disrupted at once. Suppliers pursuing these markets must therefore assess the care-delivery ecosystem rather than treating patient demand alone as an indicator of realized sales potential. Partnerships that integrate device access with safe-disposal support may become more important in public tenders.
Rational prescribing adds a separate pressure on conventional therapeutic injection volumes. When oral therapies are clinically suitable, formulary policy can reduce routine use of injectable antibiotics, analgesics, and related treatments. This does not weaken demand from insulin therapy, vaccination, or complex specialty care, but it limits the volume upside available from avoidable injections in primary-care settings.
GMI Analyst View
We view the market's outlook as more dependent on healthcare-system execution than on broad economic cycles. Chronic-care demand and vaccine programs provide a resilient foundation, but the pace of value creation will be determined by how quickly procurement systems adopt safety specifications and whether disposal infrastructure keeps pace with the expansion of single-use care delivery.
Hypodermic Syringes & Needles Market Segment Analysis
By Type
Syringes segment in the hypodermic syringes & needles market generated USD 4.70 billion in 2025 and is expected to account for 61.9% of market revenue by 2035. Their leading position reflects broad use across therapeutic delivery, vaccination, diagnostic collection, and procedural care, while the continuing migration toward safety-engineered configurations supports value growth within established institutional purchasing channels.
Needles are forecast to generate USD 4.10 billion by 2035 and accounted for 38.0% of market revenue in 2025. Demand is supported by their role as both complementary consumables and standalone products for blood collection, vaccination, and insulin administration, with gauge, length, and tip design providing meaningful product differentiation in clinical and self-care applications.
By Usability
Disposable products accounted for 91.0% of market revenue in 2025 and are forecast to generate USD 10.02 billion by 2035. Infection-prevention requirements, occupational-safety practices, and public-health procurement standards have made single-use formats the prevailing choice across regulated healthcare environments, with auto-disable and reuse-prevention devices adding further momentum.
Reusable products generated USD 682 million in 2025 and are projected to grow at a 0.9% CAGR (2026–2035). Their remaining relevance is concentrated in selected resource-constrained settings and specific multi-dose delivery uses, but wider availability of disposable formats and stronger attention to reuse-related infection risks continue to narrow the addressable base.
By Application
Drug delivery generated USD 3.33 billion in 2025 and is forecast to reach USD 4.94 billion by 2035. This application remains central to the market because inpatient, outpatient, and long-term care protocols require devices across intramuscular, subcutaneous, and intravenous administration, while biologics and specialty therapies raise the importance of reliable, safety-oriented formats.
Blood collection held 19.0% of market revenue in 2025 and is expected to grow at a 3.4% CAGR (2026–2035). Recurring diagnostic testing sustains demand across hospitals, laboratories, and diagnostic centers, although closed-system and vacuum-based collection alternatives moderate the role of traditional hypodermic formats in high-throughput settings.
Vaccination is forecast to generate USD 1.72 billion by 2035 and represented 16.0% of market revenue in 2025. Routine immunization programs provide a durable base for auto-disable syringes, while the segment's outlook balances broader coverage in lower-income countries against the normalization of emergency vaccination volumes in mature markets.
Insulin administration generated USD 1.13 billion in 2025 and is projected to expand at a 4.3% CAGR (2026–2035). Growth is supported by expanding diabetes care, higher per-patient device usage, and the adoption of pen-needle formats, particularly as self-administration moves purchasing toward pharmacies and home-care channels.
Other applications generated USD 455 million in 2025 and are forecast to reach USD 425 million by 2035. Veterinary, dental, and specialty uses remain relevant but face a comparatively constrained outlook as some legacy procedures move toward alternative delivery systems and noncritical applications experience greater cost-driven substitution.
By End Use
Hospitals generated USD 4.16 billion in 2025 and are expected to account for 53.0% of market revenue by 2035. They remain the principal demand center because of their concentration of high-acuity therapeutic, diagnostic, and surgical procedures, even as care pathways distribute a greater share of routine administration into outpatient settings.
Ambulatory surgical centers are forecast to generate USD 2.15 billion by 2035 and are projected to grow at a 4.7% CAGR (2026–2035). The shift of surgical and interventional procedures toward outpatient settings expands demand for drug preparation, anesthesia support, blood collection, and safety-compliant consumables in facilities that prioritize efficient turnover and standardized supply.
Diagnostic centers held 17.0% of market revenue in 2025 and are forecast to generate USD 1.94 billion by 2035. Their demand profile benefits from rising testing frequency for metabolic, immune, and oncology-related conditions, as well as the continued development of standalone and point-of-care diagnostic infrastructure.
Other end-use categories generated USD 758 million in 2025 and are expected to grow at a 2.6% CAGR (2026–2035). Home care, long-term care, community health centers, and veterinary settings broaden the market's demand base, although fragmented purchasing, cost sensitivity, and lower procedure intensity constrain their aggregate contribution.
GMI Analyst View
We see the segment mix evolving through internal upgrading rather than disruptive replacement. Hospitals and drug delivery retain their structural importance, yet the strongest commercial opportunities increasingly sit in settings where safety requirements, self-administration, and procedural migration raise the value of each device rather than merely increasing the number of units consumed.
Hypodermic Syringes & Needles Market Regional Analysis
North America Hypodermic Syringes & Needles Market Analysis
The hypodermic syringes & needles market in North America is forecast to generate USD 3.50 billion by 2035 and held 35.0% of global revenue in 2025. Mature hospital networks, established group purchasing structures, rigorous safety expectations, and high utilization of injectable therapies support the region's position as the largest revenue pool despite faster growth elsewhere.
U.S.
The United States generated USD 2.42 billion in 2025 and is expected to account for 29.7% of global market revenue by 2035. Demand is reinforced by hospital and ambulatory care infrastructure, biologics use, diabetes management, and well-established safety-device requirements that favor suppliers with validated products and dependable domestic distribution.
Canada
Canada generated USD 233 million in 2025 and is forecast to grow at a 3.2% CAGR (2026–2035). Publicly funded provincial health systems keep institutional procurement cost-conscious, while population aging, home-care injection programs, and chronic-disease management sustain demand for compliant devices.
Europe Hypodermic Syringes & Needles Market Analysis
Europe generated USD 1.89 billion in 2025 and is forecast to grow at a 3.5% CAGR (2026–2035). Universal healthcare systems, established procurement frameworks, and occupational-safety requirements provide a stable market base, with demographic aging and chronic-care management supporting ongoing consumption across hospital and community settings.
Germany
Germany generated USD 380 million in 2025 and is forecast to reach USD 530 million by 2035. Its extensive hospital and outpatient care network supports substantial device use across therapeutic, diagnostic, and preventive applications, while home insulin administration and biologic therapy uptake add demand in nonhospital channels.
France
France accounted for 3.8% of global market revenue in 2025 and is projected to grow at a 3.4% CAGR (2026–2035). Broad health coverage, regular vaccination activity, and diabetes management sustain recurring consumption, while centralized reimbursement and procurement structures reinforce the need for cost-effective, compliant supply.
UK
The United Kingdom is forecast to generate USD 390 million by 2035 and accounted for 3.8% of global market revenue in 2025. NHS purchasing frameworks, community-care expansion, and continued treatment of diabetes and chronic conditions outside hospital walls are supporting demand for safe, efficient injection devices.
Asia Pacific Hypodermic Syringes & Needles Market Analysis
The hypodermic syringes & needles market in Asia Pacific generated USD 2.27 billion in 2025 and is forecast to reach USD 3.54 billion by 2035. The region combines expanding chronic-disease treatment, broadening health coverage, large immunization programs, and manufacturing depth, creating significance as both a major demand market and an important global supply base.
China
China generated USD 900 million in 2025 and is expected to account for 13.3% of global market revenue by 2035. A large diabetes population, high-volume public healthcare system, and domestic production capabilities underpin demand, while biosimilar use and local procurement preferences support continued adoption across conventional and safety-engineered formats.
India
India accounted for 6.9% of global market revenue in 2025 and is forecast to grow at a 6.0% CAGR (2026–2035). Expansion is linked to diabetes care, public immunization, institutional drug delivery, and a cost-competitive domestic manufacturing base capable of supporting large public-health procurement programs.
Japan
Japan is forecast to generate USD 420 million by 2035 and accounted for 4.2% of global market revenue in 2025. A mature clinical environment, extensive use of self-administered therapies, and stringent device requirements support steady demand, with revenue progression driven more by aging-related care intensity and product specification than by new patient access.
South Korea
South Korea generated USD 190 million in 2025 and is forecast to reach USD 260 million by 2035. Advanced hospital infrastructure, increasing use of biologics, and wider home-injection programs support demand, while alignment with international safety standards encourages product upgrades across institutional and ambulatory settings.
Latin America Hypodermic Syringes & Needles Market Analysis
Latin America is forecast to generate USD 580 million by 2035 and is expected to grow at a 4.8% CAGR (2026–2035). Broader healthcare access, rising diabetes prevalence, and immunization activity support demand, although fragmented purchasing, public-budget constraints, and reliance on imported safety formats preserve strong price sensitivity across the region.
Brazil
Brazil generated USD 190 million in 2025 and is forecast to grow at a 5.0% CAGR (2026–2035). Large public-sector vaccination and therapeutic procurement programs create volume demand, while private hospitals and accreditation-driven providers are increasingly important buyers of safety-engineered devices.
Mexico
Mexico is forecast to generate USD 145 million by 2035 and accounted for 1.3% of global market revenue in 2025. National health-system procurement provides predictable demand for vaccination and chronic-care devices, but centralized purchasing places a premium on manufacturers with efficient distribution and cost discipline.
Middle East & Africa Hypodermic Syringes & Needles Market Analysis
The Middle East & Africa market generated USD 379 million in 2025 and is forecast to reach USD 550 million by 2035. Regional demand varies sharply: GCC systems can procure premium, safety-compliant formats, while many African healthcare settings face infrastructure and supply-chain limitations that constrain conversion of underlying clinical demand into device revenue.
GCC
GCC countries generated USD 152 million in 2025 and are projected to grow at a 5.0% CAGR (2026–2035). High healthcare expenditure, diabetes prevalence, hospital capacity investment, and procurement requirements for compliant devices support above-average demand for safety-oriented injection products.
South Africa
South Africa is forecast to generate USD 80 million by 2035 and accounted for 0.8% of global market revenue in 2025. Public-sector vaccination, HIV management, and therapeutic care establish a stable demand base, though budget pressures and supply-chain vulnerabilities temper the pace of market expansion.
GMI Analyst View
We believe geographic rebalancing will be a defining competitive issue through the forecast period. Mature markets continue to reward regulatory depth and premium safety portfolios, whereas Asia Pacific and selected emerging markets require a different capability set: competitive manufacturing economics, localized distribution, and the ability to serve large-scale public-health procurement without sacrificing compliance.
Hypodermic Syringes & Needles Market Share & Competitive Landscape
The hypodermic syringes & needles market share structure remains fragmented, with the top five suppliers collectively accounting for 23.5% of global revenue in 2025. Scale matters in regulated tenders and hospital contracts, but regional manufacturers and specialized producers retain meaningful positions where localized supply, price competitiveness, or application-specific design is decisive.
B. Braun Melsungen held a 7.4% market share in 2025. Its position is supported by a portfolio spanning conventional and safety syringes, infusion therapy, and needle technologies, alongside hospital relationships and manufacturing capabilities that support multi-market supply resilience.
BD (Becton, Dickinson and Company) held a 6.5% market share in 2025. The company's reach across medication delivery, safety devices, and institutional supply systems reinforces its standing in regulated healthcare markets, where product validation, distribution reliability, and integration with hospital workflows influence purchasing decisions.
HMD Healthcare accounted for 4.2% of market revenue in 2025. Its presence is rooted in high-volume auto-disable and reuse-prevention syringe production for public-health procurement, where cost efficiency, quality certification, and the capacity to fulfill large immunization orders are central competitive requirements.
Nipro and Cardinal Health contribute through distinct commercial models. Nipro's manufacturing footprint supports conventional needle supply and a growing safety-device presence in Asia Pacific, while Cardinal Health's institutional distribution network provides access to U.S. hospitals and ambulatory surgical centers. Across the wider field, Abbott, Catalent, Connecticut Hypodermics, DeRoyal, EXEL, HI-TECH MEDICS, ICU Medical, Lifelong MEDITECH, McKesson, Medline, Retractable Technologies, Terumo, VITA NEEDLE, and VMG compete through specialized formats, regional channels, supply-chain capabilities, and clinical-use positioning.
Product differentiation is increasingly linked to safety engineering, compliance credentials, and reliability under procurement scrutiny. Manufacturers with capabilities in retractable, passive-safety, auto-disable, and specialty injection formats are better positioned to defend pricing than suppliers concentrated in conventional commodity products. Distributors and private-label participants remain influential where purchasing decisions emphasize continuity of supply and contract efficiency.
Recent Industry Developments
BD (January 15, 2025): BD announced an expansion of its U.S. manufacturing network for syringes, needles, and IV catheters. The new production lines increased capacity for safety-engineered injection devices by more than 40% and conventional syringes by more than 50%, strengthening domestic availability for hospital procedures, vaccination, and drug delivery [6]BD (Becton, Dickinson and Company). “BD Boosts U.S. Manufacturing of Critical Medical Devices.” bd.com.
BD (August 4, 2025): BD announced an investment of more than USD 35 million in its Columbus, Nebraska facility as part of a broader manufacturing-capacity program. The initiative underscores the company's continued focus on domestic production capacity for essential clinical-care devices, including syringes and needles [7]BD (Becton, Dickinson and Company). “BD to Invest $35 Million in Nebraska Facility to Expand Prefilled Flush Syringe Manufacturing to Support U.S. Health Care.” bd.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →